Company History Main Article


Recognized Leaders in medical science for more than a century

Daiichi Sankyo's heritage of scientific discovery spans 110 years – from the discovery of epinephrine (also known as adrenaline) and the development of the statin class of lipid-lowering agents to the development of the first glitazone, which revolutionized long-term control of type 2 diabetes.

Today, our products are helping patients in more than 20 countries around the world including the United States, Japan, Asia and Europe. Click here to download a company history overview.

Our Legacy in the U.S.

The thousands of cherry trees that line the tidal basin in West Potomac Park aren't a natural phenomenon. They represent a cross-cultural partnership between the United States and Japan that was forged 100 years ago.

In 1912, world-famous chemist and our company's first president Dr. Jokichi Takamine, orchestrated the gift of 3,000 cherry trees from Mayor Yukio Ozaki of Tokyo to the city of Washington, D.C. as a symbol of harmony between our two nations. And while this historic gift was launched with a simple ceremony on March 27 a century ago, with First Lady Helen Herron Taft and Viscountess Chinda, wife of the Japanese ambassador, how and why the trees came to the U.S. is more intricate.

Daiichi Sankyo's connection to these trees and the collaborative role our first president played continues to inspire our company today. Not only is the gift of trees an important symbol of our philanthropic mission and our corporate culture of global collaboration, it is also an important part of our history and part of Dr. Takamine's legacy. Our partnerships have produced a pipeline of innovative medicines that will help people for years to come.

Daiichi Sankyo continues to build on Dr. Takamine's legacy by contributing to the communities where we live and work. We honor Dr. Takamine's legacy today through philanthropic and volunteer efforts that include support for science, education and access to medical care across the globe.

Daiichi Sankyo Around the Globe

Daiichi Sankyo Co., Ltd. was established in 2005 with the merger of two leading century-old pharmaceutical companies, Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. Daiichi Sankyo maintains a portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections around the world and also focuses on the discovery of novel oncology therapies. Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo, Co., LTD and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in New Jersey.

Daiichi Sankyo Europe, GhbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.

Daiichi Sankyo Timeline

Company History

  • 2014
    Ambit Biosciences

    Acquired Ambit Biosciences to expand oncology timeline

  • 2011Acquires Plexxikon

    Daiichi Sankyo Group acquires Plexxikon and enters U.S. oncology market
    Daiichi Sankyo, Inc. acquires first U.S.-based Packaging Facility, located in Pennsylvania

  • 2008
    U3 Pharma

    Acquired U3 Pharma, a company with a pipeline of targeted antibody therapeutics for cancer

  • 2006 Integrate to form Daiichi Sankyo, Inc

    Daiichi Pharmaceutical Co., Ltd. and Sankyo Co., Ltd. integrate to form Daiichi Sankyo, Inc.

  • 2005
    Agreement to merge

    Daiichi and Sankyo announce their agreement to merge, establishing Daiichi Sankyo Co., Ltd. in Japan

  • 2004 Establishes Daiichi Medical Research, Inc.

    Daiichi establishes Daiichi Medical Research, Inc. in the U.S.

  • 2001
    Sankyo Pharma Inc

    Sankyo buys out Sankyo Parke-Davis, combining all U.S. commercial operations, research and development into one organization, Sankyo Pharma Inc

  • 2000 Establishes independent operations

    Sankyo Pharma establishes independent operations in the U.S.

  • 1996
    Headquartered in New Jersey

    Sankyo sets up joint venture, Sankyo Parke-Davis, with Warner-Lambert (headquartered in New Jersey)

  • 1989 Medical development organization

    Daiichi begins establishment of medical development organization

  • 1985
    Sankyo Europe in Germany

    Sankyo establishes Sankyo Europe in Germany
    Sankyo establishes clinical research organization in New York

  • 1983 Origination of the glitazone class

    Sankyo discovers troglitazone, an insulin sensitizer, marking the origination of the glitazone class

  • 1982
    Establishes subsidiary

    Daiichi establishes its U.S. subsidiary in New York

  • 1971 First HMG-CoA reductase inhibitor

    Dr. Akira Endo of Sankyo discovers the first HMG-CoA reductase inhibitor, marking the origination of the statin class

  • 1961
    Liaison office in New York

    Sankyo establishes a liaison office in New York

  • 1918 Incorporated

    Daiichi Pharmaceutical is incorporated

  • 1913

    Sankyo Co., Ltd. is incorporated

  • 1910 Discovers vitamin B1

    Dr. Umetaro Suzuki, a Sankyo scientific advisor, discovers vitamin B1

  • 1900
    Isolate epinephrine

    Sankyo is the first company to isolate epinephrine, discovered by Sankyo's first president, Dr. Jokichi Takamine

  • 1899 Sankyo Shoten

    Sankyo Shoten, Sankyo's predecessor company, is established in Japan

Company Culture More Stories

Learn More

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability.

read more ...